On 2 September 2004, orphan designation (EU/3/04/220) was granted by the European Commission to Oncoscience AG, Germany, for anti epidermal growth factor receptor antibody h-R3 (cimazumab) for the treatment of glioma.
The sponsorship was transferred to Oncoscience GmbH, Germany, in September 2018.
Anti epidermal growth factor receptor antibody h-R3
|Disease / condition||
Treatment of glioma
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.